PMID- 31422400
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 1423-0194 (Electronic)
IS  - 0028-3835 (Linking)
VI  - 110
IP  - 5
DP  - 2020
TI  - Classification and Prognostic Stratification of Bronchopulmonary Neuroendocrine 
      Neoplasms.
PG  - 393-403
LID - 10.1159/000502776 [doi]
AB  - The accuracy and reproducibility of the World Health Organization (WHO) 2015 
      classification of bronchopulmonary neuroendocrine neoplasms (BP-NENs) is 
      disputed. The aim of this study is to classify and grade BP-NENs using the WHO 
      2019 classification of digestive system NENs (DiS-NEN-WHO 2019), and to analyze 
      its accuracy and prognostic impact. Two BP-NEN cohorts from Japan and Germany, 
      393 tumors (88% surgically resected), were reviewed and the clinicopathological 
      data of the resected tumors (n = 301) correlated to patients' disease-free 
      survival (DFS). The DiS-NEN-WHO 2019 stratified the 350 tumors into 91 (26%) 
      neuroendocrine tumors (NET) G1, 52 (15%) NET G2, 15 (4%) NET G3, and 192 (55%) 
      neuroendocrine carcinomas (NEC). NECs, but not NETs, were immunohistochemically 
      characterized by abnormal p53 (100%) and retinoblastoma 1 (83%) expression. The 
      Ki67 index, which was on average 4 times higher than mitotic count (p < 0.0001), 
      was prognostically more accurate than the mitotic count. NET G3 patients had a 
      worse outcome than NET G1 (p < 0.01) and NET G2 patients (p = 0.02), 
      respectively. No prognostic difference was detected between NET G3 and NEC 
      patients after 5 year DFS. It is concluded that stratifying BP-NEN patients 
      according to the DiS-NEN-WHO 2019 classification results in 3 prognostically 
      well-defined NET groups, if grading is solely based on Ki67 index. Mitotic count 
      alone may underestimate malignant potential of NETs.
CI  - (c) 2019 S. Karger AG, Basel.
FAU - Oka, Naomi
AU  - Oka N
AD  - Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
AD  - National Hospital Organization, Sendai Medical Center, Sendai, Japan.
FAU - Kasajima, Atsuko
AU  - Kasajima A
AD  - Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan, atsuko.kasajima@tum.de.
AD  - Department of Pathology, Technical University Munich, Munich, Germany, 
      atsuko.kasajima@tum.de.
AD  - Member of the German Cancer Consortium (DKTK), Heidelberg, Germany, 
      atsuko.kasajima@tum.de.
FAU - Konukiewitz, Bjorn
AU  - Konukiewitz B
AD  - Department of Pathology, Technical University Munich, Munich, Germany.
FAU - Sakurada, Akira
AU  - Sakurada A
AD  - Department of Thoracic Surgery, Institute of Development, Aging and Cancer, 
      Tohoku University Graduate School of Medicine, Sendai, Japan.
FAU - Okada, Yoshinori
AU  - Okada Y
AD  - Department of Thoracic Surgery, Institute of Development, Aging and Cancer, 
      Tohoku University Graduate School of Medicine, Sendai, Japan.
FAU - Kameya, Toru
AU  - Kameya T
AD  - Division of Pathology, Shizuoka Cancer Centre Hospital and Research Institute, 
      Shizuoka, Japan.
FAU - Weichert, Wilko
AU  - Weichert W
AD  - Department of Pathology, Technical University Munich, Munich, Germany.
AD  - Member of the German Cancer Consortium (DKTK), Heidelberg, Germany.
FAU - Ishikawa, Yuichi
AU  - Ishikawa Y
AD  - Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer 
      Research, Tokyo, Japan.
FAU - Suzuki, Hiroyoshi
AU  - Suzuki H
AD  - National Hospital Organization, Sendai Medical Center, Sendai, Japan.
FAU - Sasano, Hironobu
AU  - Sasano H
AD  - Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Kloppel, Gunter
AU  - Kloppel G
AD  - Department of Pathology, Technical University Munich, Munich, Germany.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20190819
PL  - Switzerland
TA  - Neuroendocrinology
JT  - Neuroendocrinology
JID - 0035665
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (MKI67 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Biomarkers, Tumor
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Ki-67 Antigen
MH  - *Lung Neoplasms/classification/diagnosis/metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading/*standards
MH  - *Neuroendocrine Tumors/classification/diagnosis/metabolism/pathology
MH  - Prognosis
MH  - World Health Organization
OTO - NOTNLM
OT  - Lung
OT  - Neuroendocrine neoplasm
OT  - World Health Organization classification
EDAT- 2019/08/20 06:00
MHDA- 2021/02/16 06:00
CRDT- 2019/08/19 06:00
PHST- 2019/03/19 00:00 [received]
PHST- 2019/08/13 00:00 [accepted]
PHST- 2019/08/20 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
PHST- 2019/08/19 06:00 [entrez]
AID - 000502776 [pii]
AID - 10.1159/000502776 [doi]
PST - ppublish
SO  - Neuroendocrinology. 2020;110(5):393-403. doi: 10.1159/000502776. Epub 2019 Aug 
      19.